You searched for "OCT"

2041 results found

Ambitions for sustainable service recovery amidst an escalating post-COVID backlog

Rod McNeil reviews plans, activity and solutions to better address the post-COVID backlog and bolster sustainable service recovery. Ophthalmology was the busiest outpatient specialty during the three years to March 2020 across the English NHS and again recorded the highest...

Virtual ophthalmic conferences: learnings from the Covid-19 pandemic

The Covid-19 pandemic was the catalyst for a number of paradigm shifts in numerous industries. The demand for proxies that follow social distancing measures created a hotbed for digital solutions and transitioned these to social convention. In the aftermath, the...

A Multidisciplinary Approach to Neovascular Glaucoma in a Patient with Waldenström’s macroglobulinemia

An 84-year-old Caucasian male attended eye casualty with a four month history of reduced vision, a dull ache and photophobia in both eyes. He had also reported dizziness, weakness and intermittent epistaxis in the nine months prior to presentation. There...

Best way to detect glaucoma progression: by reflecting on the past 25 years

Glaucoma – a condition of optic neuropathy leading to progressive visual field loss often associated with raised intraocular pressure. It is fair to say that our definition for this condition has remained unchanged over the last 25 years and the...

The Sickle Cell Retinopathy Network is leading global change in screening and management

Sickle cell disease or disorder (SCD) is one of the most neglected health conditions in the world. A strong hypothesis is that this is because SCD affects people of African, Caribbean and other Global Majority communities and has received disproportionately...

More sensitive visual acuity test for age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...

Your precious submission is awaited

It is one of the great trials of medical life trying to get things published. Where once upon a time a few case reports and being eighth author on a paper or two was more than sufficient to secure a...

Would automated pupillometry be a useful addition when assessing acute vision loss?

The authors present a two-part study, the first part being an electronic survey of ophthalmologists and optometrists to identify barriers to the routine clinical use of automated pupillometry and the second, a clinical study comparing the swinging light tests and...

EEG changes following use of cyclopentolate 1% eye drops

Cycloplegic eye drops may affect the central nervous system. This study reports electroencephalogram (EEG) changes in a cohort of 6–15-year-old children. EEG recordings were taken after placebo and two doses of cyclopentolate 1% in 24 awake children (36 children had...

Reporting the development and pilot use of fixable surgical instruments

This study reports the development of instruments to substitute traction sutures during strabismus surgery and to act in place of surgical assistance. Three types of instruments were developed: (1) fixable multi-functional forceps; (2) fixable muscle hook; and (3) fixable retractor....

An eye on novel anti-cancer agents: an evidence-based approach to external eye assessment

Novel anti-cancer therapies have led to significant advancement in cancer treatment, however, they can be associated with external eye complications. It is important to be mindful of such adverse effects during assessment of patients enrolled in clinical trials. Annually, approximately...

Gene Vision launched to support those diagnosed with genetic eye diseases

A new website, Gene Vision (https://gene.vision), has been developed by Professor Mariya Moosajee and Dr Alex Yeong, supported by Dr Peter Thomas (Director of Digital Innovation at Moorfields Eye Hospital). The new site is intended for adults, children and their families who are diagnosed with rare genetic eye diseases.